Stallergenes and Protein’eXpert collaborate for recombinant allergens

The partnership is part of the Stallergenes ‘Enhanced Allergens’ innovation program for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system.

Protein’eXpert will handle developing processes aimed at optimising the existing production protocol; developing and scaling up fermentation, renaturation, and purification processes and producing preclinical and clinical batches.

Philippe Moingeon, scientific director of Stallergenes, said: “This partnership enables us to accelerate the development of our ‘Enhanced Allergens’ program, and to envisage moving rapidly on to humans in a Phase I study.”